

25th March, 2021 – For immediate release

Medcan Australia - Medcan partners with Cann I Help to deliver Compassionate Access Program

Medcan Australia (Medcan) is pleased to announce the launch the **Compassionate Access Program**.

Medcan has been present in the Australian medicinal cannabis industry since 2016 and has found the cost of legal medications excessive meaning many patients are forced to pursue alternate solutions on the black market.

As an early mover industry participant, Medcan feel this is simply unacceptable and significant changes need to be made.

The **Compassionate Access Program** will see eligible patients, who would otherwise find the normal cost of medication prohibitive, provided with a solution. Medcan will subsidize up to 50% of the cost of selected medications with no cap on the number of patients who are eligible.

Medcan has partnered with [Cann I Help](#) to administer the **Compassionate Access Program**.

[Cann I Help](#), who is headed by Dr Laurence Kemp, are a service provider that assists patients through an Australia wide network of GPs. [Cann I Help's](#) philosophy is based around a holistic approach to patient care with [Cann I Help](#) clinicians working alongside patients regular GPs to provide training and support.

The launch of the Compassionate Access Program goes a long way to fulfilling Medcan's vision of "providing reliable, affordable access to patient specific Medicinal Cannabis Products"

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia:

Medcan Australia Founder, Craig Cochran said: "Patient access and affordability are the 2 major hurdles within the Australian medicinal cannabis space. This partnership with [Cann I Help](#) and the launch of the **Compassionate Access Program** is the first step in addressing these issues."

Comments from Dr Laurence Kemp – Head of Medical – Cann I Help:

"As the Head of Medical for Cann I Help I am delighted to announce our partnership with Medcan Australia – a partnership which will bring huge benefits to our patients and our network of doctors.

As a practising GP I regularly see patients whom I feel might benefit from a trial of medicinal cannabis treatment, but find the cost of the medications prohibitive. Patients with cancer, chronic pain or significant mental health difficulties are often out of work and on limited incomes. Often, as is so common in medicine, the patients with the greatest need for treatment seem to be the least able to access it.

Our partnership with Medcan Australia goes a long way to addressing this affordability issue. Through working closely with Medcan, as a leading supplier of medicinal cannabis products within Australia, we have been able to develop our "Compassionate Access Program." This program provides our patients a discount on the cost of any Medcan product prescribed for them by one of our doctors. The discount is determined based on the clinical need and financial circumstances of the patient, with additional points being allocated to Aboriginal or Torres Straite Islander patients who qualify for the Close the Gap initiative. With discounts of up to 50% available, on top of Medcan's already competitive pricing, this program is a potential game changer, massively enhancing the ability of patients to access medicinal cannabis products.

At Cann I Help our mission has always been about providing accessible, affordable and high-quality patient centred care. This partnership is an important milestone for us in achieving our goals.”

Background

Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan Australia are one of only a few companies in Australia to hold the full suite of ODC (Office of Drug Control) Licences, State Licences & DAWR Permits.

Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD & THC profiles to suit varying medicinal applications, with all of our products manufactured under GMP certification, ensuring consistent medicine for patients.

For further information on Medcan’s expansion plans:

<https://medcanaustralia.com.au/investorinfo/>

For Further Information please contact:



Gareth Ball
+61414860512
Po Box 4579, Springfield, QLD, Australia, 4300
gareth@medcanaustralia.com.au
www.medcanaustralia.com.au